Tumor Redox Heterogeneity-Responsive Prodrug Nanocapsules for Cancer Chemotherapy

Jinqiang Wang,Xuanrong Sun,Weiwei Mao,Weilin Sun,Jianbin Tang,Meihua Sui,Youqing Shen,Zhongwei Gu
DOI: https://doi.org/10.1002/adma.201300929
IF: 29.4
2013-01-01
Advanced Materials
Abstract:A prodrug forms nanocapsules responsive to tumor GSH/ROS heterogeneity releasing the parent drug SN38 via thiolysis in the presence of GSH (glutathione) or via enhanced hydrolysis due to ROS (reactive oxygen species)-oxidation of the linker, giving rise to high in vitro cytotoxicity and in vivo anticancer therapeutic activity. The nanocapsules are a suitable size for tumor targeting by means of the EPR effect and have a fixed SN38 loading content of 35 wt%, ideal for translational nanomedicine.
What problem does this paper attempt to address?